CYTOGEN PRESENTS DATA FROM PHASE II STUDY OF QUADRAMET
Cytogen has presented data from a Phase II study of Quadramet (samarium Sm-153
lexidronam injection), in combination with sanofi-aventis' docetaxel (Taxotere),
for the treatment of patients with hormone-refractory prostate cancer. The results
were presented at the 12th Annual Prostate Cancer Foundation Scientific Retreat
in Phoenix, Ariz.
The study, known as TAXSAM1, was designed to evaluate the toxicity and efficacy
of Quadramet in combination with docetaxel in 29 patients with progressive hormone-refractory
prostate cancer.
According to the results of the study, within 12 weeks after start of the first
TAXSAM cycle, PSA declines greater than 50 percent and 75 percent were seen
in 34 percent and 21 percent of the patients, respectively. The time from start
of the TAXSAM regimen until the PSA declines was 38 and 34 days respectively.
PSA progression was seen in 69 percent of the patients, with a median time to
PSA progression of 126 days.